DOCSLIB.ORG

Identification, Characterisation, And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification, Characterisation, And 3-3 -q1 IuBxrrFrcATroN' CUIRACTERISATION' AND MorEcuLAR ANlLYsrs oF THE ATTnRNATIvELY SPLrcEn FONUS OF THE LUTBINIZING HONMONB RNCEPTOR rN THB OvrNE OvIRY DBIN J. BnclcH B.Sc. (HoNs) A thesis submitted in total fulfilment of the requirements for the degree of Doctor of Philosophy Department of Obstetrics and Gynaecology, The FacultY of Medicine. UniversitY of Adelaide, Adelaide, South Australia J , 1996 Enur¿, At the time of submission of this thesis, the paper "Mutational analyses of the extracellular domain of the full-length Lutropin/Choriogonadotropin receptor suggests leucine-rích repeats 1-6 are involved in hormone binding" by T.homas, D., Rozell, T.G., Liu, X. and Segaloff, D.L. (1996) in Molecular Endocrinology 10:76O-768, was unavailable to the author. This paper further defines the region of LTVCG receptor that is involved in high affimty binding to hCG andLH. i.e. from amino acids -26 to 206 (Braun et al., 1991; see Tøble 1.7) to -26 to 164, with amino acids 165 to2ll being mildly important. Ío Denise, tuty Çuiling Lígfit in tfr¿, DørLest 9{ours ff not; T^lnln or ConTENTS Table of Contents................ .l Summary.. .xiii Declaration .xvi Acknowledgments .xvii Publications................ .xix Conference Presentations ............. .xx Awards .xxii List of Abbreviations used in this Thesis' .xxiii CH¡prnn ONr: Rrvrnw or rHE LnnR-lrunn 2 1. I Introduction.......... J 1.2 Physiology of the Ovary........ 1.2.1 From Primordial Germ cells to Primordial Follicles J 1.2.2 F ollicular DeveloPment 4 1.2.3 Ovulation ......... 1.2.4 Resumption of Meiosis 1.2.5 4tresia.............. 1.2.6 Follicular Steroidogenesis and its Control by Cell Type 1.2.7 The CorPus Luteum 1.2.8 Luteal Regression..........'..... 7.2.9 Lttteal Function during Pregnancy 1 . 3 Luteinizing Hormone and Chorionic Gonadotrophin......'.... " " " " 1.3.1 Regulaton of LH secretion'.' I . 3.2 Regulation of Chorionic Gonadotrophin secretion" "" " I.4LWCG Receptors. 1.4.1 Location of the LWCG Receptor... ............24 1.4.1. 1 The Testes ...,.',..'..24 1.4.1.2 Non-Gonadal Tissue ............24 l.4.2Primary Structure and Topology of the LIVCG Receptor ............28 1.4.3 Cloning of the LIVCG Receptor .,,.........33 1.4.4 Structural Organisation of the LI{/CG Receptor Gene..'..........".. ............37 1.4.5 Homology of the LIVCG Receptor with the FSH and TSH Receptors 1.4.6 Functional Properties of the LIVCG Receptor... 1.4.6.1 G Protein Activation 1.4.6.2 The cAMP PathwaY 1.4.6.3 The Phospholipase C Pathway 1.4.7 Regulation of the Functional Properties and Numbers of LIICG Receptors. 51 1.4.7.1. Uncoupling of LFVCG receptors... 52 Heterologous Uncoupling of the LIVCG receptor'........ 52 Homologous Uncoupling of the LTVCG receptor.......... s2 1 .4.7 .2. Up-Regulation of LIVCG Receptors................ 55 1,4.7 .3. Down-Regulation of the LH Receptor ......'...'.'. 57 Down-Regulation of LH Receptors in Follicles 57 Down-Regulation of LH Receptors in Luteal cells...'... 59 Down-Regulation in Leydig Cells and Leydig Tumor CeIls......... 6l 1.4.8 Structural Functions of the LIICG Receptor 65 A. Hormone binding 66 1. Amino Acid Determinants....,... 66 2. Carbohydrate Determinants 73 B. Effector Activation 76 1l 1.4.9. Heterogeneity of LFVCG Receptor Messenger RNA Transcripts ....79 1.5 Alternative Splicing............... ....81 1.5. 1. Mechanisms of Alternative Splicing'..'.........-. ....81 1.5.2. Alternative Splicing of the LFVCG Receptor Gene..' ....82 1,6 Hypothesis and Aims of the Thesis ....89 Cuerrnn Two: GnNnnel Mnrnnws AND Mtrnons 2.0 Reagents and Solutions.............. 92 2.1 Solutions for Molecular BiologY 92 2.1.1 Molecular Biology Stock Reagents and Buffers..'.'....'.'.... 92 Alkaline Lysis Buffers for Mini Preparations of Plasmid DNA......... 92 5.7 MCaesium Chloride (CsCl) Solution 93 10x Calf Intestinal Alkaline Phosphatase buffer 93 Deionised Formamide 93 50x Denhardt's solution .......'....... 93 Diethylpyrocarbonate (DEPC) treated II2O ......... 94 I M Dithiothreitol (DTT) 94 6x DNA loading buffer...'..' 94 40 mM dNTP solution ,94 Ethidium Bromide ,94 0.5 M Ethylenediaminetetra Acetic Acid (EDTA), pH 8.0..." .95 3.1 M GTC solution............. .9s Isopropylthio-B-D-galactoside (IPTG).. .. .. .95 X-gal .95 Ligase 10x buffer .96 ru Maxiprep Lytic Mix. ..96 Northern Blot Prehybridisation mixture ..96 Northern Blot Stripping Solution.............',. ..96 Phenol ..96 Phenol : Chloroform : Isoamyl alcohol...'.. ..97 Proteinase K Buffer ..97 Qiagen Buffers for Large Scale Plasmid Preparations .'.,... ..97 RNase (for general use) ..97 lOx RNA loading buffer ..98 RNase Protection Hybridisation buffer....... .. ..' ...98 RNase Protection Digestion mixture ...98 RNase Protection Formamide Loading buffer ...98 10x RNA Transblot Buffer ...98 RNA Methylene Blue stain...'...... ...99 20x SSC ...99 20x SSPE ...99 STE Buffer................ ...99 I 0x Tris-Acetate-EDTA (TAE) Buffer........... _..99 I 0x Tris-Borate-EDTA (TBE) Buffer'.. "'.. -.'.' ....99 2.l.2Bacterial Media ,...100 Ampicillin ,...100 I M CaCl2 Stocks ....100 20o/o Casamino acids. ....100 1 M MgCl2 Stocks ....100 I M MgSO4 Stocks ....100 10x M9 Salt Solution............... ....100 Glucose/lvlinimal Medium Agar Plates ......'.. ....101 Luria Bertani (LB) Medium...'..'..... ..:.101 lv Superbroth Medium.... .. r01 Special Broth Medium.... ..101 SOB Medium ............,. ..101 SOG Medium............ ..t02 TFB buffer ..102 Preparation of LB plates with ampicillin........... ..102 Converting LB Amp plates into X-gal plates........ ..102 2.2 Molecular Biology Techniques................ ..103 2.2.1 Plasmid Purification .........,.. ..103 2.2.1.1 Small Scale Plasmid Preparation . Alkaline Lysis......,.. .. 103 2.2. 1 .2 Large Scale Plasmid Preparations................ ..104 Large Scale Plasmid Preparation and Purification by CsCl gradient centrifugation........ ..104 Maxi Preparation of Plasmid DNA : Qiagen Method.... ..105 2.2.2 Restriction Endonuclease Di gestion. ., ., ., .'.. ..105 2.2.3 General procedures for RNase-free conditions. ..106 DEPC-treatment of soluttons... ...106 2.2.4 Preparation of Total RNA......... ...106 RNA Isolation by CsCl Gradient Centrifugation............ ...107 RNA Isolation by the Morrison Method'.... ...107 2.2.5 Quantitation of DNA and RNA ...108 2.2.6 Polymerase Chain Reaction (PCR)....... ..,109 Primer Design.... ...109 Synthesis and isolation of oligonucleotides. ...109 Standard amplífi cation conditions ...111 2.2.7 Fiev erse-Transcriptase Polymerase Chain Reaction (RT-PCR) ...111 2.2.8 Gel Electrophoresis.............., ...1t2 Agarose gel electroPhoresis ...t12 v Polyacrylamide gel electrophoresis ..........' tt2 2.2.9 Synthesis of RNA probes....... tt2 In vitro transcription of RNA probes....... t12 Determining 32p-Utp incorporation ............. ll3 2.2.10 RNA Analysis by Northern Blotting.... 113 Preparation of samPles 113 RNA electrophoresis for Northern blotting tt4 Electrotransfer of RNA to nylon filters tt4 Staining nylon filters for RNA.... l14 Filter hybridisation.............. 115 Washing the filter and autoradiography.'.. 11s Re-use of blots 1r6 2.2.1I Cloning and subcloning of DNA fragments........'....... ,116 Isolation of DNA fragments from TAE gels and from solution 116 End filling restriction enzyme generated 5' overhangs .. "..'..'...... l17 Dephosphorylation of linearised vector DNA 118 Lígation of DNA 118 2.2.12 Transformation of E. Coli cells .......... 118 Hanahan's Transformation of E col¡ ljll4l09 118 Preparation of competent DH5cr, E. coli cells for electroporation............ 119 Transformation of competent DH5a E- Col¡ cells by electroPoration............ 119 2.2.I3 Analysis of Transformants...... r20 Screening bacterial colonies for recombinant plasmids using PCR.......... ..120 2.2.14 Sequencing ..t21 VI Sequencing gels ........... t2r 2.2.15 RNase Protection assays 12l Analysis of RNase Protection Assays 123 2.3 Solutions for Polyclonal Antibody Production t23 2.3.1 Polyclonal Antibody Production Stock Solutions. 123 Phosphate Buffered Saline (PBS) 123 Normal Saline 123 Antibody AssaY Buffer....'.. 123 2.4 Polyclonal Antibody Production Techniques ......... t23 2.4.1 Peptide design. 123 2.4.2 Animals............. 124 2.4.3 Immunisation Protocol.... t24 2.4.4 Collection of Serum........... t2s 2.4.5 lodination of peptides t25 IodogenrM coating of tubes .t25 Iodination of peptides .t2s Purification of the iodinated peptides.,. .126 2.4.6 Isolation of IgG .126 2.4.7 Determining Antibody Titre ......... .127 2.5 Protein Analysis Solutions.. .127 2.5.1 Protein Analysis Stock Solutions.. .127 Transblot buffer .t27 Acrylamide gel stain .127 Acrylamide gel destain .............. .128 Acrylamide gel Preservative .128 SDS-Acrylamide Gel Running Buffer .. .t28 2x Denaturing Sample Buffer............... .128 4x SDS Running Gel Buffer .t28 vll 4x SDS Stacking Gel Buffer Tris-Tricine SDS-PAGE Anode buffer.............. Tris-Tricine SDS-PAGE Cathode buffer ...... "'.. 3x Tris-Tricine SDS-PAGE Gel buffer..... Nitrocellulose Protein Stain.... "... Nitrocellulose Protein Destain....' Homogenisation Buffer 4".......... Homogenisation Buffer B ..'......... Homogenisation Buffer C.........'.. Western Blot Buffers'.'.'..."'..' Bouins Fixative Solution.... 2.6 Protein Analysis... 2.ó. I Protein Isolation General Homogenisation Method..'........' Microsomal Preparation ....'.'........ 2.6.2 Quantitation of Proteins 2.6.3 lodination of Goat anti-Rabbit Antibodies 2.6.4 SDs-Polyacrylamide Gel Electrophoresis . Staining Acrylamide Gels 2.6.5 Protein Analysis
Load more

Recommended publications
  • Constitutive Activation of G Protein-Coupled Receptors and Diseases: Insights Into Mechanisms of Activation and Therapeutics
    Pharmacology & Therapeutics 120 (2008) 129–148 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: S. Enna Constitutive activation of G protein-coupled receptors and diseases: Insights into mechanisms of activation and therapeutics Ya-Xiong Tao ⁎ Department of Anatomy, Physiology and Pharmacology, 212 Greene Hall, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA article info abstract The existence of constitutive activity for G protein-coupled receptors (GPCRs) was first described in 1980s. In Keywords: 1991, the first naturally occurring constitutively active mutations in GPCRs that cause diseases were reported G protein-coupled receptor Disease in rhodopsin. Since then, numerous constitutively active mutations that cause human diseases were reported Constitutively active mutation in several additional receptors. More recently, loss of constitutive activity was postulated to also cause Inverse agonist diseases. Animal models expressing some of these mutants confirmed the roles of these mutations in the Mechanism of activation pathogenesis of the diseases. Detailed functional studies of these naturally occurring mutations, combined Transgenic model with homology modeling using rhodopsin crystal structure as the template, lead to important insights into the mechanism of activation in the absence of crystal structure of GPCRs in active state. Search for inverse Abbreviations: agonists on these receptors will be critical for correcting the diseases cause by activating mutations in GPCRs. ADRP, autosomal dominant retinitis pigmentosa Theoretically, these inverse agonists are better therapeutics than neutral antagonists in treating genetic AgRP, Agouti-related protein AR, adrenergic receptor diseases caused by constitutively activating mutations in GPCRs. CAM, constitutively active mutant © 2008 Elsevier Inc.
    [Show full text]
  • Neurotransmitter and Neuropeptide Regulation of Mast Cell Function
    Xu et al. Journal of Neuroinflammation (2020) 17:356 https://doi.org/10.1186/s12974-020-02029-3 REVIEW Open Access Neurotransmitter and neuropeptide regulation of mast cell function: a systematic review Huaping Xu1, Xiaoyun Shi2, Xin Li3, Jiexin Zou4, Chunyan Zhou5, Wenfeng Liu5, Huming Shao5, Hongbing Chen5 and Linbo Shi4* Abstract The existence of the neural control of mast cell functions has long been proposed. Mast cells (MCs) are localized in association with the peripheral nervous system (PNS) and the brain, where they are closely aligned, anatomically and functionally, with neurons and neuronal processes throughout the body. They express receptors for and are regulated by various neurotransmitters, neuropeptides, and other neuromodulators. Consequently, modulation provided by these neurotransmitters and neuromodulators allows neural control of MC functions and involvement in the pathogenesis of mast cell–related disease states. Recently, the roles of individual neurotransmitters and neuropeptides in regulating mast cell actions have been investigated extensively. This review offers a systematic review of recent advances in our understanding of the contributions of neurotransmitters and neuropeptides to mast cell activation and the pathological implications of this regulation on mast cell–related disease states, though the full extent to which such control influences health and disease is still unclear, and a complete understanding of the mechanisms underlying the control is lacking. Future validation of animal and in vitro models also is needed, which incorporates the integration of microenvironment-specific influences and the complex, multifaceted cross-talk between mast cells and various neural signals. Moreover, new biological agents directed against neurotransmitter receptors on mast cells that can be used for therapeutic intervention need to be more specific, which will reduce their ability to support inflammatory responses and enhance their potential roles in protecting against mast cell–related pathogenesis.
    [Show full text]
  • G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes
    Int. J. Mol. Sci. 2014, 15, 1112-1142; doi:10.3390/ijms15011112 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes Benoît T. Roux 1 and Graeme S. Cottrell 2,* 1 Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK; E-Mail: [email protected] 2 Reading School of Pharmacy, University of Reading, Reading RG6 6UB, UK * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-118-378-7027; Fax: +44-118-378-4703. Received: 4 December 2013; in revised form: 20 December 2013 / Accepted: 8 January 2014 / Published: 16 January 2014 Abstract: G protein-coupled receptors (GPCRs) are important cell signaling mediators, involved in essential physiological processes. GPCRs respond to a wide variety of ligands from light to large macromolecules, including hormones and small peptides. Unfortunately, mutations and dysregulation of GPCRs that induce a loss of function or alter expression can lead to disorders that are sometimes lethal. Therefore, the expression, trafficking, signaling and desensitization of GPCRs must be tightly regulated by different cellular systems to prevent disease. Although there is substantial knowledge regarding the mechanisms that regulate the desensitization and down-regulation of GPCRs, less is known about the mechanisms that regulate the trafficking and cell-surface expression of newly synthesized GPCRs. More recently, there is accumulating evidence that suggests certain GPCRs are able to interact with specific proteins that can completely change their fate and function. These interactions add on another level of regulation and flexibility between different tissue/cell-types.
    [Show full text]
  • Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
    Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners.
    [Show full text]
  • CGRP Signaling Via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia
    International Journal of Molecular Sciences Article CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia 1,2 1,2, 1,2, 1,2 Tobias Gluexam , Alexander M. Grandits y, Angela Schlerka y, Chi Huu Nguyen , Julia Etzler 1,2 , Thomas Finkes 1,2, Michael Fuchs 3, Christoph Scheid 3, Gerwin Heller 1,2 , Hubert Hackl 4 , Nathalie Harrer 5, Heinz Sill 6 , Elisabeth Koller 7 , Dagmar Stoiber 8,9, Wolfgang Sommergruber 10 and Rotraud Wieser 1,2,* 1 Division of Oncology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; [email protected] (T.G.); [email protected] (A.M.G.); [email protected] (A.S.); [email protected] (C.H.N.); [email protected] (J.E.); thomas.fi[email protected] (T.F.); [email protected] (G.H.) 2 Comprehensive Cancer Center, Spitalgasse 23, 1090 Vienna, Austria 3 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany; [email protected] (M.F.); [email protected] (C.S.) 4 Institute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria; [email protected] 5 Department for Cancer Research, Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria; [email protected] 6 Division of Hematology, Medical University of Graz, Auenbruggerplatz
    [Show full text]
  • Calcitonin Gene-Related Peptide and Other Peptides
    P1: KWW/KKL P2: KWW/HCN QC: KWW/FLX T1: KWW GRBT050-16 Olesen- 2057G GRBT050-Olesen-v6.cls July 9, 2005 4:30 ••Chapter 16 ◗ Calcitonin Gene-Related Peptide and Other Peptides Susan Brain and Lars Edvinsson Vasoactive peptides can be either stored or synthesized de THE CGRP FAMILY OF PEPTIDES novo before release from a range of tissues in the brain or from the walls of intracranial vasculature. In this chapter, The expression of mRNA from the calcitonin gene is tissue we concentrate on neuropeptides that are released from specific in that CGRP mRNA is predominantly expressed perivascular nerves. These include calcitonin gene-related in nerves and calcitonin mRNA in the thyroid (5). The 37 peptide (CGRP), substance P, neurokinin A, nociceptin, amino acid peptide CGRP belongs to a family that include somatostatin, and opioids (Table 16-1). The endothelium the more recently discovered peptides adrenomedullin produces the potent vasoconstrictors endothelin and an- that is primarily produced by non-neuronal tissues, espe- giotensin, and dilators such as nitric oxide, prostacyclin, cially vascular tissues and amylin that is mainly produced and endothelium-derived hyperpolarizing factors. In ad- in the pancreas. They share some structural homology (ap- dition there are circulating agents; among these the most proximately 25–40%) and also some, but not total, similar- potent is 5-hydroxytryptamine. The neuronal messengers ities in biological activities (see Brain and Grant [11] for stored in the intracranial vessels have been reviewed recent review). CGRP is abundant in the body and has a (32) and it was revealed that sympathetic nerves store wide distribution throughout the central and peripheral noradrenaline, neuropeptide Y, and ATP, the parasympa- nervous systems.
    [Show full text]
  • Calcitonin Gene-Related Peptide Regulates Expression of Neurokinin1 Receptors by Rat Spinal Neurons
    1816 • The Journal of Neuroscience, March 1, 2003 • 23(5):1816–1824 Calcitonin Gene-Related Peptide Regulates Expression of Neurokinin1 Receptors by Rat Spinal Neurons Virginia S. Seybold,1 Kenneth E. McCarson,2 Paul G. Mermelstein,1 Rachel D. Groth,1 and Lia G. Abrahams1 1Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, and 2Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160 Although neurokinin 1 (NK1) receptors contribute to hyperalgesia, and their expression is increased in the spinal cord during peripheral inflammation, little is known regarding the signaling molecules and the second messenger pathways that they activate in regulating the expression of the NK1 receptor gene. Because the promoter region of the NK1 receptor contains a cAMP response element (CRE), we tested the hypothesis that calcitonin gene-related peptide (CGRP) regulates the expression of NK1 receptors via a pathway involving activation of the transcription factor cAMP response element binding protein (CREB). Experiments were conducted on primary cultures of neonatal rat spinal neurons. Treatment of cultures with CGRP for 8–24 hr increased 125I-substance P binding on spinal neurons; the increase in binding was preceded by an elevation in NK1 receptor mRNA. The CGRP-induced change in 125I-substance P binding was concentration-dependent and was inhibited by the antagonist CGRP8–37. CGRP increased phosphorylated CREB immunoreactivity and CRE-dependent transcription in neurons, indicating the involvement of the transcription factor CREB. Evidence that CGRP increased cAMP levels in spinal neurons and that the protein kinase A inhibitor H89 attenuated CGRP-induced CRE-dependent transcription suggests that the intracellular pathway stimulated by CGRP leads to activation of protein kinase A.
    [Show full text]
  • Characterization of Two Patched Receptors for the Vertebrate Hedgehog Protein Family
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 13630–13634, November 1998 Cell Biology Characterization of two patched receptors for the vertebrate hedgehog protein family DAVID CARPENTER*, DONNA M. STONE†,JENNIFER BRUSH‡,ANNE RYAN§,MARK ARMANINI†,GRETCHEN FRANTZ§, ARNON ROSENTHAL†, AND FREDERIC J. DE SAUVAGE*¶ Departments of *Molecular Oncology, ‡Molecular Biology, §Pathology, and †Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080 Communicated by David V. Goeddel, Tularik, Inc., South San Francisco, CA, September 24, 1998 (received for review June 12, 1998) ABSTRACT The multitransmembrane protein Patched mammalian hedgehogs or whether ligand-specific components (PTCH) is the receptor for Sonic Hedgehog (Shh), a secreted exist. Interestingly, a second murine PTCH gene, PTCH2, was molecule implicated in the formation of embryonic structures isolated recently (25) but its function as a hedgehog receptor and in tumorigenesis. Current models suggest that binding of has not been established. To characterize PTCH2 and com- Shh to PTCH prevents the normal inhibition of the seven- pare it with PTCH with respect to the biological function of the transmembrane-protein Smoothened (SMO) by PTCH. Ac- various hedgehog family members, we isolated the human cording to this model, the inhibition of SMO signaling is PTCH2 gene. Binding analysis shows that both PTCH and relieved after mutational inactivation of PTCH in the basal PTCH2 bind to all three hedgehog ligands with similar affinity. cell nevus syndrome. Recently, PTCH2, a molecule with Furthermore PTCH2 interacts with SMO, suggesting that it sequence homology to PTCH, has been identified. To charac- can form a functional multicomponent hedgehog receptor terize both PTCH molecules with respect to the various complex similar to PTCH-SMO.
    [Show full text]
  • G Protein-Coupled Receptors at the Crossroad Between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts
    International Journal of Molecular Sciences Review G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts Ernestina M. De Francesco 1,2, Federica Sotgia 3, Robert B. Clarke 2, Michael P. Lisanti 3 and Marcello Maggiolini 1,* ID 1 Department of Pharmacy, Health and Nutrition Sciences, University of Calabria via Savinio, 87036 Rende, Italy; [email protected] 2 Breast Cancer Now Research Unit, Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Wilmslow Road, Manchester M20 4GJ, UK; [email protected] 3 Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre, University of Salford, Greater Manchester M5 4WT, UK; [email protected] (F.S.); [email protected] (M.P.L.) * Correspondence: [email protected]; Tel.: +39-0984-493076 Received: 30 October 2017; Accepted: 11 December 2017; Published: 14 December 2017 Abstract: G protein-coupled receptors (GPCRs) have been implicated in transmitting signals across the extra- and intra-cellular compartments, thus allowing environmental stimuli to elicit critical biological responses. As GPCRs can be activated by an extensive range of factors including hormones, neurotransmitters, phospholipids and other stimuli, their involvement in a plethora of physiological functions is not surprising. Aberrant GPCR signaling has been regarded as a major contributor to diverse pathologic conditions, such as inflammatory, cardiovascular and neoplastic diseases. In this regard, solid tumors have been demonstrated to activate an angiogenic program that relies on GPCR action to support cancer growth and metastatic dissemination. Therefore, the manipulation of aberrant GPCR signaling could represent a promising target in anticancer therapy.
    [Show full text]
  • Signal Transmission Pathways Inside G Protein-Coupled Receptors
    molecules ReviewReview Signaling withinwithin AllostericAllosteric Machines:Machines: SignalSignal TransmissionTransmission PathwaysPathways InsideInside GG Protein-Coupled Protein-CoupledReceptors Receptors 11,, 1,21,2 11 Damian BartuziBartuzi 1,*,* AgnieszkaID , Agnieszka A. Kaczor A. Kaczor and1,2 andDariusz Dariusz Matosiuk Matosiuk 1 11 1 DepartmentDepartment of of Synthesis Synthesis and and Chemical Chemical Technology Technology ofof PharmaceuticalPharmaceutical Substances Substanceswith with Computer Computer Modelling ModellingLab, Medical Lab, University Medical University of Lublin, of 4A Lublin, Chod´zkiStr., 4A Chodźki Lublin Str., PL20093, Lublin Poland; PL20093, Poland;; [email protected]@umlub.pl (A.(A. (A.A.K.);A.K.); [email protected] [email protected] (D.M.)(D.M.) (D.M.) 22 2 SchoolSchool of of Pharmacy, Pharmacy, University University of of Eastern Eastern Finland, Finland, Yliopistonranta Yliopistonranta 1, 1, P.O. P.O. Box Box 1627, 1627, Kuopio FI--70211, FinlandKuopio FI-70211, Finland ** Correspondence:Correspondence: [email protected] [email protected];;; Tel.: Tel.: +48 +48-81-448-7270--81--448--7270 AcademicAcademic Editor:Editor: YungYung HouHou WongWong Received: 13 April 2017 2017;;; Accepted: 10 July 2017 2017;;; Published: date 15 July 2017 Abstract:Abstract: InIn recentrecent years,years, ourour understandingunderstanding of functionfunction of GG protein-coupledprotein--coupled receptors receptors (GPCRs) (GPCRs) has changedchanged from aa picturepicture
    [Show full text]
  • The Role of Gpcrs in Bone Diseases and Dysfunctions
    Bone Research www.nature.com/boneres REVIEW ARTICLE OPEN The role of GPCRs in bone diseases and dysfunctions Jian Luo 1, Peng Sun1,2, Stefan Siwko3, Mingyao Liu1,3 and Jianru Xiao4 The superfamily of G protein-coupled receptors (GPCRs) contains immense structural and functional diversity and mediates a myriad of biological processes upon activation by various extracellular signals. Critical roles of GPCRs have been established in bone development, remodeling, and disease. Multiple human GPCR mutations impair bone development or metabolism, resulting in osteopathologies. Here we summarize the disease phenotypes and dysfunctions caused by GPCR gene mutations in humans as well as by deletion in animals. To date, 92 receptors (5 glutamate family, 67 rhodopsin family, 5 adhesion, 4 frizzled/taste2 family, 5 secretin family, and 6 other 7TM receptors) have been associated with bone diseases and dysfunctions (36 in humans and 72 in animals). By analyzing data from these 92 GPCRs, we found that mutation or deletion of different individual GPCRs could induce similar bone diseases or dysfunctions, and the same individual GPCR mutation or deletion could induce different bone diseases or dysfunctions in different populations or animal models. Data from human diseases or dysfunctions identified 19 genes whose mutation was associated with human BMD: 9 genes each for human height and osteoporosis; 4 genes each for human osteoarthritis (OA) and fracture risk; and 2 genes each for adolescent idiopathic scoliosis (AIS), periodontitis, osteosarcoma growth, and tooth development. Reports from gene knockout animals found 40 GPCRs whose deficiency reduced bone mass, while deficiency of 22 GPCRs increased bone mass and BMD; deficiency of 8 GPCRs reduced body length, while 5 mice had reduced femur size upon GPCR deletion.
    [Show full text]
  • NIH Public Access Author Manuscript Arterioscler Thromb Vasc Biol
    NIH Public Access Author Manuscript Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2010 May 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Arterioscler Thromb Vasc Biol. 2009 May ; 29(5): 650±656. doi:10.1161/ATVBAHA.109.185066. G-protein coupled receptors as potential drug targets for lymphangiogenesis and lymphatic vascular diseases William P Dunworth1,2 and Kathleen M Caron1,2 1Department of Cell and Molecular Physiology, 111 Mason Farm Road, 247 Medical Biomolecular Research Bldg., Room 6340B, CB # 7545 The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA 2Department of Genetics, 111 Mason Farm Road, 247 Medical Biomolecular Research Bldg., Room 6340B, CB # 7545 The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA Abstract G-protein coupled receptors (GPCRs) are widely expressed cell surface receptors that have been successfully exploited for the treatment of a variety of human diseases. Recent studies in genetically engineered mouse models have led to the identification of several GPCRs important for lymphatic vascular development and function. The adrenomedullin receptor, which consists of an oligomer between calcitonin receptor-like receptor and receptor activity modifying protein 2, is required for normal lymphatic vascular development and regulates lymphatic capillary permeability in mice. Numerous studies also suggest that lysophospholipid receptors are involved in the development of lymphatic vessels and lymphatic endothelial cell permeability. Given our current lack of pharmacological targets for the treatment of lymphatic vascular diseases like lymphedema, the continued identification and study of GPCRs in lymphatic endothelial cells may eventually lead to major breakthroughs and new pharmacological strategies for the treatment of lymphedema.
    [Show full text]